We have developed an innovative exosome-based vaccine platform featuring a novel antigen-determinant discovery technology that has been shown to elicit specific IgG responses and long-lived non-exhausted effector memory T-cell responses. This asset has been IP protected.

The aim of INNOVEX THERAPEUTICS S.L. is the development of new vaccines against infectious diseases based on extracellular vesicles as novel antigen discovery and delivery platforms.